BRAF Inhibition Generates a Host–Tumor Niche that Mediates Therapeutic Escape
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The current study defines a fibroblast-derived niche that facilitates the therapeutic escape of melanoma cells from BRAF inhibition. Vemurafenib treatment led to the release of TGF-β from the melanoma cells that increased the differentiation state of the fibroblasts; an affect associated with fibronectin deposition, increase in α-smooth muscle actin (α–SMA) expression and the release of neuregulin (NRG). At the same time, vemurafenib directly activated the fibroblasts through paradoxical stimulation of the MAPK pathway, causing them to secrete hepatocyte growth factor (HGF). Treatment with the BRAF/MEK inhibitor combination reversed the release of HGF. Adhesion of melanoma cells to fibronectin was critical in amplifying the fibroblast-derived NRG and HGF-mediated PI3K/AKT survival signaling in the melanoma cells following BRAF inhibition. In co-culture studies, combination treatment with inhibitors of BRAF/MET/HER kinase was ineffective at reversing the fibroblast-mediated therapeutic escape from BRAF inhibition. Instead, it was noted that combined BRAF/PI3K inhibition overcame fibroblast-mediated drug resistance in vitro and was associated with enhanced anti-tumor effects in an in vivo xenograft model. Thus, we show melanoma cells and fibroblasts remodel their microenvironment in response to BRAF inhibition and that these adaptations allow tumor cells to evade therapy through increased PI3K/AKT survival signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Self-citationA Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770 · cited 1×
“There is already evidence that both HGF and NRG limit responses to vemurafenib and its analogue PLX4720 (Abel et al., 2013; Sharma et al., 2010; Straussman et al., 2012).”
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
Self-citationWidespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134 · cited 2×
“Our emerging understanding of therapeutic resistance suggests a role for both tumor autonomous mechanisms as well as adaptive pro-survival signals from the host microenvironment (Abel et al., 2013; Lito et al., 2012; Straussman et al., 2012; Wilson et al., 2012).”
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., et al. (2014) · Nature · doi:10.1038/nature13121 · Cited by 888 · cited 1×
“Recent reports have suggested that TGF-β released from melanoma cells upon BRAF inhibition may also increase RTK expression in melanoma cells (Sun et al., 2014).”
Ilić, D., Almeida, E. A. C., Schlaepfer, D. D., Dazin, P., Aizawa, S., & Damsky, C. H. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.2.547 · Cited by 495 · cited 1×
“Fibroblast survival is dependent upon attachment to an appropriate ECM, with adhesion to FN constituting a major survival signal (Almeida et al., 2000; Ilic et al., 1998; Lin et al., 2011; Zhang et al., (Postlethwaite et al., 1981).”
Cited by
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888
“465 When treated with Emurafenib, melanoma cells release TGF-β , triggering fi broblasts to increase expression levels of α -smooth muscle actin ( α -SMA), neuregulin (NRG), and fi bronectin.”
BackgroundBRAF — a tumour-agnostic drug target with lineage-specific dependencies
Hanrahan, A. J., Chen, Z., Rosen, N., & Solit, D. B. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00852-0 · Cited by 136
“260–262).”
Bai, X., Fisher, D. E., & Flaherty, K. T. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0204-6 · Cited by 107
Self-citationDeterminants and functions of CAFs secretome during cancer progression and therapy
Linares, J., Marín-Jiménez, J. A., Badia-Ramentol, J., & Calon, A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.621070 · Cited by 110
“For instance, specific secretion of HGF and neuregulin (NRG)-1 by fibroblasts upon exposure to vemurafenib -a BRAF inhibitorwas reported in melanoma (Fedorenko et al., 2015).”
BackgroundSeip, K., Fleten, K. G., Barkovskaya, A., Nygaard, V., Haugen, M. H., Engesæter, B. Ø., Mælandsmo, G. M., & Prasmickaite, L. (2016) · Oncotarget · doi:10.18632/oncotarget.7671 · Cited by 41
“In line with our observations, several recent studies showed that stroma-promoted BRAFi resistance involves the PI3K pathway [37, 39].”
Metadata
- Authors
- Fedorenko, I. V., Wargo, J. A., Flaherty, K. T., Messina, J. L., & Smalley, K. S. M.
- Venue
- Journal of Investigative Dermatology
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 135
- Issue
- 12
- Pages
- 3115-3124
- ISSN
- 0022-202X (ISSN-L)
- OpenAlex
- W1957521115
- Cited by
- 105
- References
- 7
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BRAF Inhibition Generates a Host–Tumor Niche that Mediates Therapeutic Escape. https://app.cochat.ai/papers/10.1038/jid.2015.329
- The paper
- Fedorenko, I. V., Wargo, J. A., Flaherty, K. T., Messina, J. L., & Smalley, K. S. M. (2015). BRAF Inhibition Generates a Host–Tumor Niche that Mediates Therapeutic Escape. Journal of Investigative Dermatology. https://doi.org/10.1038/jid.2015.329
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.